Incidence of Kidney Disease

RECENT NEWS
NPR  Dec 18  Comment 
A new report looks at the top causes of death in 188 countries. Infectious diseases are less of a threat than in 1990 — but please, look both ways before you cross the street.
FierceBiotech  Dec 12  Comment 
A year after former partner GlaxoSmithKline closed the door on what could have been a $1.5 billion collaboration, Mountain View, CA's ChemoCentryx is touting a Phase II victory for its kidney disease treatment, news that promptly doubled its share...
Wall Street Journal  Dec 10  Comment 
DSI Renal, a company that provides dialysis care to patients with chronic kidney failure and renal disease, is on the auction block and could fetch about $1 billion including debt.
Benzinga  Dec 2  Comment 
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on bringing innovative therapies to market for patients with renal disease, today announced the publication of Auryxia phase 2 clinical trial results in...
Forbes  Nov 21  Comment 
Two new agents under development may help curb and prevent elevated potassium levels, the common and serious side effect of drugs that inhibit the renin-angiotensin-aldosterone system (RAAS). These drugs, which include the popular ACE inhibitors...
MedPage Today  Nov 17  Comment 
(MedPage Today) -- No benefit to combining ACE inhibitor with ARB in polycystic kidney disease.
New York Times  Nov 8  Comment 
A longtime forklift driver has not let kidney disease alter his career path. The job, he says, “gives me a sense of purpose.”
MedPage Today  Oct 3  Comment 
(MedPage Today) -- Utility of troponin T and NT-proBNP confirmed in kidney disease patients.
Benzinga  Sep 25  Comment 
Akebia Therapeutics, Inc. (NASDAQ: AKBA), a biopharmaceutical company focused on the development of novel, proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with...
MedPage Today  Sep 24  Comment 
(MedPage Today) -- CKD need not prohibit thrombolytic therapy in otherwise eligible stroke patients.




 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki